Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell ...
Hosted on MSN1mon
Medigene AG Advances with Equity Agreement to Boost CapitalMedigene ( (DE:MDG1)) has issued an update. Medigene AG has announced the execution of the first tranche of a Standby Equity Purchase Agreement with Yorkville Advisors Global, LP. This move will ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today ...
Martinsried, Germany and Montréal, Canada (pta008/02.12.2021/07:30 UTC+1) Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical-stage immuno-oncology company focusing on the development ...
EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback